0001415889-24-007534.txt : 20240311
0001415889-24-007534.hdr.sgml : 20240311
20240311180020
ACCESSION NUMBER: 0001415889-24-007534
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eldridge George A
CENTRAL INDEX KEY: 0001413006
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 24739466
MAIL ADDRESS:
STREET 1: C/O TARGANTA THERAPEUTICS CORPORATION
STREET 2: 222 THIRD STREET SUITE 2300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-03112024_060307.xml
X0508
4
2024-03-07
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001413006
Eldridge George A
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
SEE REMARKS
1
Common Stock
2024-03-07
4
M
0
22386
2.14
A
24346
D
Common Stock
2024-03-07
4
S
0
22386
25.0017
D
1960
D
Common Stock
2024-03-08
4
M
0
114
2.14
A
2074
D
Common Stock
2024-03-08
4
S
0
114
25
D
1960
D
Common Stock
2024-03-11
4
M
0
3433
2.14
A
5393
D
Common Stock
2024-03-11
4
S
0
3423
25.2423
D
1970
D
Common Stock
2024-03-11
4
S
0
10
26.305
D
1960
D
Stock Option (Right to Buy)
2.14
2024-03-07
4
M
0
1400
0
D
2031-04-01
Common Stock
1400
28263
D
Stock Option (Right to Buy)
2.14
2024-03-07
4
M
0
20986
0
D
2031-04-01
Common Stock
20986
58877
D
Stock Option (Right to Buy)
2.14
2024-03-08
4
M
0
114
0
D
2031-04-01
Common Stock
114
58763
D
Stock Option (Right to Buy)
2.14
2024-03-11
4
M
0
3433
0
D
2031-04-01
Common Stock
3433
55330
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.289, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Officer Title: Chief Financial Officer and Treasurer
/s/ George A. Eldridge
2024-03-11